absorption

(redirected from drug absorption)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia.
Related to drug absorption: Drug distribution

Absorption

1. The total demand for all goods and services in an economy. One calculates the absorption by adding the value of all goods and services produced and consumed locally to that of all imports.

2. A French term for acquisition.

absorption

the sharing of indirect costs or OVERHEADS to units of product by means of COST RATES. Provided that actual overheads do not exceed BUDGET and that actual output is the same as budgeted output, then the overhead cost rate should allow total product cost to be determined, and a selling price set which will recover the overhead costs involved in producing and selling the product. See STANDARD COST, OVERHEAD COST VARIANCE.
Mentioned in ?
References in periodicals archive ?
The database also includes pharmaceutical companies, biotech companies, CROs, hospitals, government labs and other organisations active in the Oral Drug Absorption research field.
Maven Semantic: Oral Drug Absorption Database
Leading organisations in Drug Absorption research include:
Maven Semantic: Drug Absorption Research Database
Yeager further added, "The results of this new study with our topical ketoprofen formulation show that we can overcome the topical drug absorption problem traditionally associated with ketoprofen.
NexMed Presents Scientific Paper At AAPS
AMPYRA([TM]) was developed using Elan Drug Technologies Oral Controlled Release MXDAS([TM])(MatriX Drug Absorption System) technology and will be marketed in the United States by Acorda Therapeutics and by Biogen Idec in markets outside the U.
Elan Drug Technologies Welcomes the NDA Approval of MS Drug AMPYRA[TM] (Dalfampridine) Extended Release Tablets
The transporter feature further advances the Simcyp Simulator's ability to reflect 'real-life' population variability in the processes of drug absorption, distribution, metabolism and excretion (ADME) through the conduct of studies in virtual human populations.
Simcyp Enhances Flagship Simulator in Line with Pharmaceutical Industry Priorities
The absorption module was constructed to simulate the physiological process of drug absorption, and incorporates human physiological parameters.
Trega Biosciences Licenses iDEA(TM) Absorption Module to Tibotec Group; Trega's Drug Discovery Products Appeal to Emerging Pharmaceutical Company
and CLEVELAND -- Absorption Systems LP, the authority on drug absorption, and ChanTest, the leading experts in ion channels, GPCRs (G-protein coupled receptors) and in vitro cardiac risk assessment, today announced they will collaborate to expand Absorption Systems' suite of drug metabolism studies to provide data on the impact that a therapy may have on the heart.
Absorption Systems and ChanTest Collaborate to Add Ion Channel Interaction Studies to the Absorption Systems Safety Suite[TM]
CIMA previously completed bioavailability studies in animals that indicated the potential for increasing the rate and extent of drug absorption with the OraVescent technology.
CIMA Announces Positive Human Study Results for Its OraVescent(TM) Technology
Burton, also the CEO and CSO of ADMETRx, is an internationally recognized thought-leader in modeling drug absorption and a frequent invited lecturer to numerous national and international symposia.
Renowned Scientist from ADMETRx Joins Advisory Board of Locus Pharmaceuticals
A key feature of the new module is that it uses data from in vitro studies with Caco-2 cells to predict drug absorption in the body.
Trega Biosciences Launches Enhanced Version of Its iDEA(TM) Predictive Model for Drug Absorption
By utilizing potassium bicarbonate as a localized buffer, DBT enables diclofenac to enter the bloodstream more quickly, resulting in a faster rate of drug absorption and increased peak plasma concentrations while not increasing the total amount of drug exposure for the patient compared to currently marketed reference drug, Cataflam([R]).
ProEthic Pharmaceuticals Announces Positive Phase III Clinical Trial Results for Fast-Acting Migraine Product Candidate
Nasdaq: TRGA), a company focused on commercializing technologies and products for accelerating drug discovery and development, today announced that following a successful validation study of its IDEA(TM) predictive model for drug absorption, F.
Trega Biosciences' IDEA(TM) Predictive Model Licensed by Roche Following Successful Validation Study

Financial browser ?
Full browser ?